Abstract
Purpose:
Drug resistance severely compromises therapeutic efficacy in hepatocellular carcinoma (HCC); however, the selection of precise treatment strategies for patients remains a critical unmet clinical need. This study investigated PANoptosis-related mechanisms underlying HCC progression to identify actionable therapeutic targets and optimize patient-specific treatment outcomes.
Patients and methods:
Multi-omics analysis (single-cell/bulk RNA sequencing) combined with machine learning was used to identify the PANoptosis-related prognostic features. The association of PANoptosis-related expression with the tumor immune microenvironment and drugs was explored using bioinformatic analysis and experimental studies.
Results:
High PANoptosis risk exhibited immunosuppressive microenvironments and therapeutic resistance. The PANoptosis-related gene YIF1B has emerged as a dual prognostic biomarker and tumor driver that promotes proliferation, and is linked to immune dysfunction and drug resistance.
Conclusion:
YIF1B may be a promising therapeutic target. This PANoptosis framework bridges molecular mechanisms to clinical management, offering strategies for personalized HCC therapy and overcoming treatment resistance.